context: A high prevalence of psychological morbidity and maladaptive personality as well as impaired quality of life (QoL) is observed in patients with and without hydrocortisone dependency following (cured) Cushing's syndrome. However, it is currently unclear whether a similar pattern is present in patients with chronic glucocorticoid replacement for primary adrenal insufficiency (PAI). objective: To evaluate psychological functioning, personality traits, and QoL in patients with PAI. design and subjects: A cross-sectional study including 54 patients with stable treatment for PAI and 54 healthy matched controls. Both patients and controls completed questionnaires on psychological functioning (Apathy Scale, Irritability Scale, Mood and Anxiety Symptoms Questionnaire short-form, and Hospital Anxiety and Depression Scale), personality traits (Dimensional Assessment of Personality Pathology short-form), and QoL (Multidimensional Fatigue Inventory, Short-Form 36, EuroQoL-5D, Nottingham Health Profile, and Physical Symptom Checklist).
results: Patients with PAI suffered from more psychological morbidity (i.e. irritability and somatic arousal) and QoL impairments compared with controls (all P<0.01). There were no differences regarding maladaptive personality traits between patients and controls. However, there was a strong and consistent positive association between the daily hydrocortisone dose and prevalence of maladaptive personality traits (i.e. identity problems, cognitive distortion, compulsivity, restricted expression, callousness, oppositionality, rejection, conduct problems, social avoidance, narcissism, and insecure attachment, all P<0.05). There was also a strong relation between the mean daily hydrocortisone dose and both psychological morbidity (i.e. depression, P<0.05) and QoL impairments (i.e. general health perception, several measures of physical functioning, and vitality, all P<0.05).
conclusion: Patients with stable glucocorticoid replacement therapy for PAI report psychological morbidity and impaired QoL. Psychological morbidity, impaired QoL, and maladaptive personality traits were all associated with higher hydrocortisone dosages.
InTroducTIon
Primary adrenal insufficiency (PAI) is characterized by insufficient secretion of glucocorticoids and mineralocorticoids, most frequently caused by autoimmunity or following bilateral adrenalectomy. Replacement therapy consists of hydrocortisone, fludrocortisone, and sometimes, additional DHEA replacement.
Cortisol has a crucial function in the central nervous system via stimulation of both the mineralocorticoid-(MRs) and glucocorticoid receptors (GRs). An appropriate balance between the activation of these two receptors is necessary for adequate stress responses, including behavioral adaptations. Imbalance between MR and GR activations might enhance vulnerability to disease in predisposed individuals. The current notion is that the effects of glucocorticoids binding to MR and GR include an inverted u-shape dose-response curve, indicating that both pathologically low and high cortisol levels negatively affect the mediating functions of these receptors as is the absence of physiological circadian pulsatile secretion (1) . The negative influence of glucocorticoid excess on psychological functioning in humans is clearly evident during active Cushing's disease since serious co-morbid psychopathology, such as major depression and anxiety is prevalent (2) . Although these symptoms improve substantially after correction of cortisol excess, consistent residual impairments persist, even after prolonged cure of cortisol excess. This is reflected by an increased prevalence of psychopathology and maladaptive personality traits as well as impairments in quality of life (QoL) (3-7) in many patients, either hydrocortisone dependent or independent.
Conversely, it is possible that previous exposure to insufficient glucocorticoid levels and current imperfections in replacement therapy in mimicking the pulsatile secretion of cortisol, such as in PAI, may also be associated with persistent psychosocial effects, considering the inverted u-shape of optimal corticosteroid receptor function. However, in contrast to the large number of reports in patients with Cushing's syndrome, less is known about the effects of previous insufficient cortisol exposure on psychological functioning and QoL in PAI (see Table 1 for an overview). Heijmans and de Ridder (1998) reported a significant relation between personality-related variables (i.e. optimism/pessimism, locus of control) and illness perceptions (8) . However, there are no studies on personality traits in patients with PAI. To date, studies in patients with PAI have demonstrated impaired QoL (9) (10) (11) (12) (13) (14) (15) , and a higher risk for the development of affective disorders such as depression or bipolar disorder (16) . The QoL impairments in patients with PAI have been attributed, at least in part, to intrinsic imperfections of hormone replacement therapy (12) . In accordance, some studies demonstrated a positive effect of DHEA replacement on QoL (13, (17) (18) (19) . On the other hand, strategies aiming at adjusting cortisol replacement therapy mimicking a more diurnal profile by adjusting the time and frequency of hydrocortisone intake did not positively affect QoL (9, 11, 20) . Furthermore, dosages above 30 mg hydrocortisone per day were associated with worse subjective health status (11) . Patients on a 10-5-5 regimen scored worse on a unit designed questionnaire compared with controls. Compared with the general population, patients had worse QoL, regardless of HC regimen. In addition, total QoL score was worse in patients on a 10-5-5 mg regimen, but there were no differences when patients were on a 20-0-10 mg regimen. Patients with current or previous drug or alcohol abuse or with neurological problems were excluded. A total of 54 participants were included in this study (21 men and 33 women).
The mean age of the patients was 50±12 years. Each patient was asked to provide a control person of comparable gender, age (+/-10 years), and educational level in order to create a control group. The self selection of controls enabled a perfect match for an additional parameter, i.e. social-economic status. Exclusion criteria for controls were present or previous drugs/alcohol abuse or neurological problems.
PAI had been diagnosed based on the classical clinical symptoms and biochemical confirmation of adrenal insufficiency in the presence of increased ACTH concentrations. Adrenal insufficiency was diagnosed when basal cortisol concentrations were below the reference range of normal (<0.12umol/l) or below 500 nmol/l after stimulation with ACTH. Forty-four patients (82%) had been diagnosed with PAI due to autoimmune disease with positive autoantibodies against adrenal cortex, five patients (9%) had been diagnosed with PAI due to non-autoimmune causes (e.g. congenital adrenal aplasia, adrenal calcification), and two patients (4%) were treated with bilateral adrenalectomy for pheochromocytomas. The origin of PAI was unknown for three patients (5%).
The Medical Ethics Committee of the LUMC approved the protocol and written informed consent was obtained from all subjects.
Questionnaires
Both patients and controls were asked to complete the following questionnaires on psychological functioning, personality traits and QoL at home and to return the questionnaires in a prepaid envelope.
The Apathy Scale consists of 14 questions on a 4-point scale measuring different features of apathy in the two previous weeks. The score for each item ranges from 0 (no apathy) to 3 (maximum intensity of apathy). The total score ranges from 0-42 points, with higher scores indicating greater apathy. A total score ≥14 points is being used to characterize subjects as apathetic (21, 22) .
The Irritability Scale consists of 14 items measuring different features of irritability in the two previous weeks. The total score ranges from 0-42 points, with higher scores indicating greater irritability. A total score ≥14 points is being used to characterize subjects as irritable (22) .
The Mood and Anxiety Symptoms Questionnaire short-form (MASQ-30) assesses symptoms that occur in mood and anxiety disorders subdivided into the three subscales negative affect, lack of positive affect and somatic arousal. The scores for each subscale ranges from 10-50, with higher scores indicating more severe negative affect, more positive affect or more somatic arousal. There are no formal cut-off scores (23) .
The Hospital Anxiety and Depression Scale (HADS) consists of 14 items, and both the anxiety and the depression subscale scores range from 0-21 points. Higher scores indicate more severe anxiety and/or depression. A score >8 points on one of the subscales is being used to characterize subjects as being anxious or depressed, respectively (24, 25) . The Physical Symptom Checklist (PSC) assesess 55 physical symptoms that are mentioned in the DSM-III classification (32) . The presence of symptoms is rated on a severity scale from 0 to 3. We excluded the gender specific items (n=4) from the analyses to rule out bias by gender. The total symptom score ranges from 0 to 153. A higher score indicates more (severe) physical symptoms in the preceding week (33) . 
Psychological functioning and quality of life (Table 4)
Patients with PAI had a higher total score on the Irritability Scale (P=0.004) compared with matched controls. Patients also showed higher scores on the somatic arousal subscale of the MASQ-30 (P=0.003). Clinically significant apathy and irritability (a score of ≥ 14 on the Apathy Scale and on the Irritability Scale) was present in 35% and 33% of patients, respectively, and significantly more irritability was observed in patients than in controls (P=0.01). On the HADS, 11% of patients had a score of ≥ 8 on the anxiety subscale and 6% on the depression subscale. This is indicative for the presence of clinically relevant anxiety or depression, respectively.
There were no significant differences between patients and controls on the depression subscale, anxiety subscale or total HADS score. 
Personality traits
The scores of the patients on the DAPPs personality traits were not different from those of the matched controls.
The association with daily hydrocortisone intake ( Table 5) Higher hydrocortisone intake was associated with lower psychological well-being, more maladaptive personality traits, and more impaired QoL. More specifically, a higher hydrocortisone dose was associated with more depressive symptoms (HADS Depression subscale, β=0.282, P=0.038), as well as decreased physical functioning (β=-0.365, P=0.008), more 
dIscussIon
This study demonstrates that patients with stable treatment for PAI suffer from more psychological morbidity with irritability and somatic arousal, in addition to impairments of QoL compared with matched healthy controls. However, personality traits were not different between patients and controls, which indicates that personality traits in patients with PAI, in contrast to psychological functioning, are not sensitive to the effects of a chronic disease, such as PAI and its pharmacological treatment in contrast to psychological morbidity. To our knowledge, this is the first study on personality traits in patients with PAI. Interestingly, there was a strong and consistent association between the mean daily hydrocortisone dose and the prevalence of maladaptive personality traits, like cognitive distortion, identity problems, and compulsivity, and also with restricted expression, callousness, oppositionality, rejection, social avoidance and narcissism. Furthermore, there was a strong positive relation between the mean daily hydrocortisone intake and reported psychological morbidity (i.e. depression) and QoL impairments (i.e. several measures of physical functioning, and pain).
Previous studies by our group have shown similar results with regard to psychological functioning and QoL in patients in long-term remission of Cushing's disease, though patients in remission of Cushing's disease also showed more maladaptive personality traits than their matched controls (3) (4) (5) 35) . These observations suggest that psychological functioning and QoL indeed follow the inverted u-shape dose response curve of cortisol exposure related to MR and GR activation, whereas this is not the case for personality traits and lower cortisol levels. Intriguingly, higher daily hydrocortisone intake seemed to be strongly associated with maladaptive personality traits, indicating that hydrocortisone intake does have a considerable effect on personality traits in patients with adrenal insufficiency.
Our findings regarding QoL are in line with the results of previous studies on decreased QoL in patients with adrenal insufficiency (9, 14, 36, 37) and the self-reported impact of the disease or treatment on subjective health status (38) . In addition, several QoL studies demonstrated that inadequate hydrocortisone replacement dosages and, especially, a high hydrocortisone dosages negatively affected QoL (11, 37, 39, 40) . Accordingly, we found negative effects of high hydrocortisone intake on QoL in patients with PAI. Intriguingly, we also found a negative effect of high hydrocortisone intake on psychological morbidity and the prevalence of maladaptive personality traits.
In healthy individuals cortisol is secreted in a pulsatile fashion with a superimposed circadian rhythm. It is actually impossible to mimic this normal pattern of hormonal secretion by hydrocortisone replacement. These imperfections in pharmacotherapy are, at least in part, associated with persisted vague complaints and a decreased QoL (9) . The importance of mimicking the circadian rhythm of cortisol secretion in patients with adrenal insufficiency, is supported by a study of Johannsson et al., which demonstrated that patients treated with once-daily dual release hydrocortisone tablets, had a more circadian-based cortisol profile, and had more favorable scores on questionnaires assessing psychological well-being and fatigue, compared to patients treated with conventional hydrocortisone treatment (41) .
Furthermore, both Lovas et al. (42) and Oksnes et al. (43) reported that continuous hydrocortisone infusion in patients with PAI resulted in cortisol and ACTH levels towards normal circadian levels and positively affected QoL. These two studies suggest that the physiological profile might be related to QoL outcomes.
A previous study by Thomsen et al., (16) reported an increased risk for developing affective disorders (e.g. depression, bipolar disorder) in hospitalized patients with adrenal insufficiency. In our cohort of patients with stable PAI, we did not find differences in depressive symptoms between patients and healthy controls. However, considering the fact that we did find other psychological morbidity (i.e. irritability and somatic arousal), we postulate that even after correction of hypocortisolism, patients with PAI remain vulnerable for developing psychological and, in particular, mood symptoms.
Recently, female gender, manifestation at older age, more autoimmune comorbidities, and latency between first symptoms and diagnosis were found to negatively affect QoL in patients with adrenal insufficiency (44) . Our data indicate that the amount of daily hydrocortisone intake should also be included as a potential influencing factor of QoL. Nevertheless, because of the exploratory nature of our study, future research is needed to provide more insight in predictors of reduced QoL in patients with adrenal insufficiency and to further distinguish whether the QoL impairments are caused by the disease itself or its treatment. In addition to the focus on research about somatic predictor variables, researchers should pay attention to potential psychological contributing factors, such as negative illness perceptions and ineffective coping strategies, because recent data have indicated that negative illness perceptions were related to a decreased QoL inpatients in long-term remission of Cushing's diseases (45) .
A possible limitation of the present study is the cross-sectional design, which does not preclude that maladaptive personality traits and QoL impairments were already present before onset of the disease. Furthermore, we cannot simply conclude that high hydrocortisone intake causes a decreased QoL, since it might be that high hydrocortisone dosages were prescribed because patients suffered from psychological symptoms or a decreased QoL.
Therefore, future studies should use a longitudinal design to enable the evaluation of the course of psychological functioning, QoL, and personality, and of the influence of adaptations in hydrocortisone intake on these three domains over time. A longitudinal design might also elucidate the interesting discrepancy between our finding that personality traits of patients with PAI do not differ from healthy controls, whereas higher daily hydrocortisone intake is significantly associated with maladaptive personality traits in patients with PAI.
In summary, patients with stable treatment for PAI report psychological morbidity and impaired QoL. There is a positive association between the daily hydrocortisone intake and the presence of psychological morbidity, maladaptive personality traits and QoL impairments.
These results point toward the possibility to intertwine psychosocial parameters in care for patients with endocrine replacement in general, and for patients with adrenal insufficiency
